Related Experiment Video
Updated: Apr 18, 2026
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
High-density lipoprotein oxidation in type 2 diabetic patients and young patients with premature myocardial
G Sartore1, R Seraglia2, S Burlina1
1Department of Medicine - DIMED, University of Padova, Italy.
Insights
Oxidative changes in Apolipoprotein A-I (ApoA-I) increase coronary heart disease (CHD) risk. This study found higher oxidized ApoA-I in type 2 diabetes and CHD patients, suggesting increased HDL oxidation.
Area of Science:
- Cardiovascular Science
- Metabolomics
- Oxidative Stress Research
Background:
- Oxidative modification of Apolipoprotein A-I (ApoA-I) diminishes the anti-atherogenic properties of High-Density Lipoprotein (HDL).
- Understanding these modifications is crucial for assessing cardiovascular disease (CVD) risk.
Purpose of the Study:
- To investigate differences in methionine sulfoxide (MetO) content within ApoA-I of HDL.
- To compare MetO levels in HDL-ApoA-I between young patients with coronary heart disease (CHD), type 2 diabetes mellitus (T2DM), and healthy individuals.
Main Methods:
- Lipid profiles were assessed in 21 T2DM patients, 23 young CHD patients, and 21 healthy volunteers.
- Methionine sulfoxide (MetO) content in ApoA-I was quantified using MALDI/TOF/TOF mass spectrometry.
- Oxidized ApoA-I (OxApoA-I) levels were determined as a percentage of total ApoA-I.
Main Results:
- MALDI spectra revealed a higher relative abundance of Met(112)O in ApoA-I from HDL of T2DM and CHD patients compared to controls.
- OxApoA-I levels did not correlate significantly with lipoproteins across all groups.
- A strong correlation was observed between the duration of diabetes and OxApoA-I levels in T2DM patients.
Conclusions:
- The study provides evidence of elevated HDL oxidation in individuals at high risk for CHD.
- Increased MetO residues in plasma ApoA-I indicate heightened oxidative stress.
- Investigating MetO levels in ApoA-I may offer valuable insights into CHD pathogenesis and risk assessment.
Background And Aims:
ApoA-I can undergo oxidative changes that reduce anti-atherogenic role of HDL. The aim of this study was to seek any significant differences in methionine sulfoxide (MetO) content in the ApoA-I of HDL isolated from young patients with coronary heart disease (CHD), type 2 diabetics and healthy subjects.
Methods And Results:
We evaluated the lipid profile of 21 type 2 diabetic patients, 23 young patients with premature MI and 21 healthy volunteers; we determined in all patients the MetO content of ApoA-I in by MALDI/TOF/TOF technique. The typical MALDI spectra of the tryptic digest obtained from HDL plasma fractions all patients showed a relative abundance of peptides containing Met(112)O in ApoA-I in type 2 diabetic and CHD patients. This relative abundance is given as percentages of oxidized ApoA-I (OxApoA-I). OxApoA-I showed no significant correlations with lipoproteins in all patients studied, while a strong correlation emerged between the duration of diabetic disease and OxApoA-I levels in type 2 diabetic patients.
Conclusions:
The most remarkable finding of our study lies in the evidence it produced of an increased HDL oxidation in patients highly susceptible to CHD. Levels of MetO residues in plasma ApoA-I, measured using an accurate, specific method, should be investigated and considered in prospective future studies to assess their role in CHD.
Related Concept Videos
01:26Coronary Artery Disease II: Pathophysiology
01:30Coronary Artery Disease I: Introduction
01:24Type II Diabetes II: Pathophysiology
01:26Type II Diabetes I: Introduction
01:26Coronary Artery Disease IV: Preventive Measures
01:26Atherosclerosis III: Management